摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-5-(4-(3-methylmorpholino)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine

中文名称
——
中文别名
——
英文名称
(S)-5-(4-(3-methylmorpholino)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
英文别名
5-[4-[(3S)-3-methylmorpholin-4-yl]-6-[(4-methylsulfonylpiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine
(S)-5-(4-(3-methylmorpholino)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine化学式
CAS
——
化学式
C23H29F3N8O3S
mdl
——
分子量
554.596
InChiKey
AFUFOYSAHFAROX-HNNXBMFYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    38
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    131
  • 氢给体数:
    1
  • 氢受体数:
    13

反应信息

  • 作为反应物:
    描述:
    (S)-5-(4-(3-methylmorpholino)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine三乙胺 作用下, 以 四氢呋喃氯仿 为溶剂, 反应 5.0h, 生成 (S)-methyl (5-(4-(3-methylmorpholino)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate mesylate
    参考文献:
    名称:
    PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
    摘要:
    本发明涉及一种吡咯并[2,1-f][1,2,4]三嗪化合物,其异构体或药学上可接受的盐、酯或水合物,以及其制备方法和应用。吡咯并[2,1-f][1,2,4]三嗪化合物具有一般式(I)表示的结构。一般式(I)表示的吡咯并[2,1-f][1,2,4]三嗪化合物可以抑制磷脂酰肌醇-3激酶(PI3K)信号通路,因此可用于制备用于治疗磷脂酰肌醇-3激酶相关疾病如癌症的药物。
    公开号:
    US20150141644A1
  • 作为产物:
    参考文献:
    名称:
    Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors
    摘要:
    In various human cancers, PI3Ks pathway is ubiquitously dysregulated and thus become a promising anti-cancer target. To discover new potent and selective PI3K inhibitors as potential anticancer drugs, new pyrrolo[2,1-f][1,2,4]triazines were designed, leading to the discovery of compound 37 (CYH33), a selective PI3Kα inhibitor (IC50 = 5.9 nM, β/α, δ/α,γ/α = 101-, 13-, 38-fold). Western blot analysis confirmed that compound 37 could inhibit phosphorylation of AKT in human cancer cells to modulate the cellular PI3K/AKT/mTOR pathway. And further evaluation in vivo against SKOV-3 xenograft models demonstrated that a dose-dependent antitumor efficacy was achieved.
    DOI:
    10.1016/j.ejmech.2020.112913
点击查看最新优质反应信息

文献信息

  • Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
    申请人:Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    公开号:US09447101B2
    公开(公告)日:2016-09-20
    The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
    本发明涉及一种吡咯并[2,1-f][1,2,4]三嗪化合物、其异构体或其药学上可接受的盐、酯或水合物,以及其制备方法和应用。该吡咯并[2,1-f][1,2,4]三嗪化合物具有通式(I)所表示的结构。通式(I)所表示的吡咯并[2,1-f][1,2,4]三嗪化合物能够抑制磷脂酰肌醇-3激酶(PI3K)信号通路,因此可用于制备治疗磷脂酰肌醇-3激酶相关疾病如癌症的药物。
  • PYRROLO[2,1-F[1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHODS AND APPLICATIONS THEREOF
    申请人:Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    公开号:US20170000800A1
    公开(公告)日:2017-01-05
    The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
  • US9447101B2
    申请人:——
    公开号:US9447101B2
    公开(公告)日:2016-09-20
  • US9724352B2
    申请人:——
    公开号:US9724352B2
    公开(公告)日:2017-08-08
  • PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
    申请人:Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    公开号:US20150141644A1
    公开(公告)日:2015-05-21
    The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
    本发明涉及一种吡咯并[2,1-f][1,2,4]三嗪化合物,其异构体或药学上可接受的盐、酯或水合物,以及其制备方法和应用。吡咯并[2,1-f][1,2,4]三嗪化合物具有一般式(I)表示的结构。一般式(I)表示的吡咯并[2,1-f][1,2,4]三嗪化合物可以抑制磷脂酰肌醇-3激酶(PI3K)信号通路,因此可用于制备用于治疗磷脂酰肌醇-3激酶相关疾病如癌症的药物。
查看更多

同类化合物

瑞德西韦5号中间体 吡咯并[2,1-f][1,2,4]三嗪-2,4(1H,3H)-二酮 吡咯并[2,1-F][1,2,4]三嗪-4-胺 吡咯并[2,1-F][1,2,4]三嗪-2,4-二胺 吡咯(1,2-A)-1,3,5-三嗪-2,4(1H.3H)-二酮 N-((4-氯吡咯并[2,1-f][1,2,4]三嗪-5-基)甲基)-N,N-二乙基乙铵溴化物 7-碘吡咯并[2,1-F][1,2,4]三嗪-4-胺 7-甲基吡咯并[2,1-f][1,2,4]三嗪-4(1H)-酮 7-甲基吡咯并[1,2-f][1,2,4]噻嗪-4-胺 7-溴-4-氯吡咯并[2,1-f][1,2,4]三嗪 7-溴-4-氯-2-(甲硫基)吡咯并[2,1-F][1,2,4]三嗪 7-溴-3H,4H-吡咯[2,1-f][1,2,4]三嗪-4-酮 7-溴-2-氯吡咯并[2,1-f][1,2,4]三嗪 7-溴-2-(甲硫基)吡咯并[2,1-f][1,2,4]三嗪 7-溴-2,4-二氯吡咯并[2,1-f][1,2,4]三嗪 7,8-二氢吡咯并[1,2-a][1,3,5]三嗪-2,4(3H,6H)-二酮 6-羟基-5-甲基-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮 6-碘1H,2H,3H,4H-吡咯并[2,1-F][1,2,4]三嗪-2,4-二酮 6-硝基吡咯并[2,1-f][1,2,4]三嗪-2,4(1h,3h)-二酮 6-溴吡咯并[2,1-f][1,2,4]三嗪-4-胺 6-溴-4-氯-吡咯并[2,1-f][1,2,4]三嗪 6-溴- 吡咯并[2,1-f][1,2,4]三嗪-2,4(1h,3h)-二酮 6-氰基-5-(1-甲基乙基)吡咯并[2,1-f][1,2,4]噻嗪-4(3H)-酮 6-氯3H-吡咯并[2,1-F][1,2,4]噻嗪-4-酮 5-甲基-4-氧代-3,4-二氢吡咯并[1,2-F][1,2,4]三嗪-6-羧酸乙酯 5-甲基-4-氧代-1,4-二氢吡咯并[2,1-f][1,2,4]三嗪-6-甲酸甲酯 5-甲基-4-(甲硫基)吡咯并[1,2-F][1,2,4]三嗪 5-溴吡咯并[1,2-f][1,2,4]噻嗪-4-胺 5-溴-4-氯吡咯并[2,1-f][1,2,4]三嗪 5-溴-3H,4H-吡咯并[2,1-f][1,2,4]三嗪-4-酮 5-溴-2-(甲基硫烷基)吡咯并[2,1-f][1,2,4]三嗪 5-氯-吡咯并[2,1-f][1,2,4]噻嗪-4(1H)-酮 5-乙基-4-羟基吡咯并[1,2-f][1,2,4]三嗪-6-羧酸盐 5,6-二甲基-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮 4-溴吡咯并[1,2-f][1,2,4]三嗪 4-氯吡咯并[2,1-f][1,2,4]三嗪-6-甲酸甲酯 4-氯吡咯并[2,1-f][1,2,4]三嗪-2-羧酸乙酯 4-氯吡咯并[2,1-F][1,2,4]三嗪-5-腈 4-氯吡咯并[2,1-F][1,2,4]三嗪-5-羧酸乙酯 4-氯吡咯并[1,2-f][1,2,4]三嗪-6-羧酸乙酯 4-氯吡咯并[1,2-F][1,2,4]三嗪 4-氯-5-甲基吡咯并[2,1-f][1,2,4]三嗪 4-氯-5-甲基吡咯并[1,2-F][1,2,4]三嗪-6-羧酸乙酯 4-氯-5-甲基吡咯[2,1-F][1,2,4]三嗪-6-羧酸甲酯 4-氯-5-异丙基吡咯并[1,2-F][1,2,4]三嗪 4-氯-5-乙基-吡咯并[2,1-f][1,2,4]三嗪-6-羧酸乙酯 4-氯-5-(1-甲基乙基)-吡咯并[2,1-f][1,2,4]噻嗪-6-羧酸乙酯 4-氯-2-碘吡咯并[1,2-f][1,2,4]三嗪 4-氯-2-甲基吡咯并[1,2-F][1,2,4]三嗪 4-氯-2-(甲硫基)吡咯并[2,1-F][1,2,4]三嗪